Developer neurodegenerative drugs designed to slow the progression of neurodegenerative diseases. The company's drug consists of dual incretin receptors that assist to slow disease progression, enabling patients to treat Parkinson's and Alzheimer's diseases.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Early Stage VC (Series A) | $6.08M | Upcoming | Startup | |||
3. Grant | 10-Dec-2019 | 00000 | 00.000 | Completed | Startup | |
2. Accelerator/Incubator | 29-May-2019 | $1.53M | Completed | Startup | ||
1. Accelerator/Incubator | 07-Feb-2019 | $1.53M | $1.53M | Completed | Startup |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Christian Hölscher | Co-Founder, Chief Scientific Officer & Board Member | ||
Mikael Thomsen Ph.D | Co-Founder & CDO | ||
Ian Laquian | Co-Founder & Chief Executive Officer |
Name | Representing | Role | Since |
---|---|---|---|
Christian Hölscher | Kariya Pharmaceuticals | Co-Founder, Chief Scientific Officer & Board Member | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Innovationsfonden | Venture Capital | Minority | 000 0000 | 000000 0 | |
Copenhagen Bio Science Park | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
BioInnovation Institute (BII) | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |